Haoming Qiu, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-2171

Appointment: (585) 396-6180

Office: (585) 275-5625

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Accepting New Patients

Biography

Professional Background

Dr. Haoming (Carl) Qiu is a radiation oncologist at the University of Rochester Medical Center seeing patients at both Wilmot Cancer Center in Rochester and Sands Cancer Center in Canandaigua. Dr. Qiu received his medical education at the Johns Hopkins University School of Medicine in Baltimore, MD and completed his residency in radiation oncology at the University of Rochester Medical Center. Dr. Qiu brings a high level of technical expertise along with a friendly and optimistic attitude in caring for his patients.

Dr. Qiu also provides radioligand therapy including:

1.Lutathera (lutetium Lu 177 dotatate) PRRT (Peptide Receptor Radionuclide Therapy) for patients with neuroendocrine tumors
2. Pluvicto (lutetium Lu 177 PSMA-617) for patients with prostate cancer

If you are interested in a consultation, please have your doctor call our office for a referral. (585) 275-5625.

Research

Dr. Qiu's research is focused on the use of radiation therapy in the treatment of gastrointestinal and lung cancers with a special focus on the use of stereotactic body radiotherapy (SBRT) to deliver ablative doses of radiation with high levels of precision and conformality.. Dr. Qiu also directs the palliative radiation service at URMC, providing treatments aimed at alleviating symptoms for patients with advanced cancers

Dr. Qiu is the author of several peer reviewed articles and has presented his research at numerous national and international meetings in oncology.

Credentials

Education

2011
MD | Johns Hopkins University

Post-doctoral Training & Residency

07/01/2013 - 06/30/2016
Residency in Radiation Oncology at University of Rochester Medical Center

07/02/2012 - 06/30/2013
Residency in Radiation Oncology at Loyola University Medical Center

06/23/2011 - 06/22/2012
Internship in Internal Medicine at Sinai Hospital Of Baltimore

VIEW ALL

Awards

2015
Roentgen Resident/Fellow Research Award
Sponsor: RSNA Research and Education Foundation
Location: University of Rochester Medical Center

2011
Excellence in Medical Student Research
Location: Johns Hopkins University School of Medicine

Clinical Trials

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC),An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Lead Researcher: Haoming Qiu

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study.

View Study Details

A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Lead Researcher: Haoming Qiu

This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.

View Study Details

Publications

Journal Articles

2022
Mills BN; Qiu H; Drage MG; Chen C; Mathew JS; Garrett-Larsen J; Ye J; Uccello TP; Murphy JD; Belt BA; Lord EM; Katz AW; Linehan DC; Gerber SA. "Modulation of the human pancreatic ductal adenocarcinoma immune microenvironment by stereotactic body radiotherapy". Clin Cancer Res. 2022; 28(1): 150-162.

2/2021
Komisarof J, Qiu H, Velez MJ, Mulford D. "Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review." Molecular and clinical oncology.. 2021 Feb; 14(2):34. Epub 2020 Dec 22.

2021
Battaglia NG; Uccello TP; Hughson A; Garrett-Larsen J; Caldon JJ; Qiu H; Gerber SA; Lord EM. "Co-administration of a clinically relevant dexamethasone dosage with ablative radiotherapy reduces peripheral lymphocytes but does not alter in vivo intratumoral lymphocyte phenotype or inhibit efficacy of radiotherapy in a murine colorectal tumor model." International journal of radiation oncology, biology, physics. 2021; 111(1): 284-296.

Books & Chapters

2021
Chapter Title: Programed Death Receptor-1 (PD-1)
Book Title: Medical Radiology: Radiation Oncology: Advances in Radiation Oncology in Lung Cancer
Author List: Qiu H, Chen Y
Edited By: Jeremic B
Published By: Springer 2021 in New York

2021
Chapter Title: Oligometastatic Disease – Basic Aspects and Clinical Results
Book Title: Medical Radiology: Radiation Oncology: Advances in Radiation Oncology in Lung Cancer
Author List: Sakthivel G, Singh DP, Qiu H, Milano MT
Edited By: Jeremic B
Published By: Springer 2021

VIEW ALL PUBLICATIONS